Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214

International Journal of Oncology

Volumn 50, Issue 2, 2017, Pages 708-716

  Li, Jian Hua ^a,b   Zhang, Su Qin ^a   Qiu, Xing Guang ^a   Zhang, Shui Jun ^a   Zheng, Shou Hua ^a   Zhang, Dan Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Henan Key Laboratory of Digestive Organ Transplantation   (China)

Author keywords

Lncrna; Mirna 214; NEAT1; Thyroid cancer cells

Indexed keywords

BETA CATENIN; LONG UNTRANSLATED RNA; MICRORNA 214; NUCLEAR ENRICH ABUNDANT TRANSCRIPT 1; UNCLASSIFIED DRUG; ARGINASE; MICRORNA; MIRN214 MICRORNA, HUMAN; NEAT1 LONG NON-CODING RNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; THYROID CARCINOMA; TUMOR PROMOTION; TUMOR VOLUME; UPREGULATION; ANIMAL; CELL PROLIFERATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; RAW 264.7 CELL LINE; THYROID TUMOR; TUMOR CELL LINE;

ANIMALS; ARGINASE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; RAW 264.7 CELLS; RNA, LONG NONCODING; THYROID NEOPLASMS;

EID: 85013040073     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3803     Document Type: Article

References (57)

1. Amphlett B, Lawson Z, Abdulrahman GO Jr, White C, Bailey R, Premawardhana LD and Okosieme OE: Recent trends in the incidence, geographical distribution, and survival from thyroid cancer in Wales, 1985-2010. Thyroid 23: 1470-1478, 2013.
2. Chen AY, Jemal A and Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115: 3801-3807, 2009.
3. Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167, 2006.
4. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214, 2009.
6. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, et al: Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26: 879-885, 2002.
7. Grebe SK and Hay ID: Thyroid cancer nodal metastases: Biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5: 43-63, 1996.
8. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS and Epstein AL: BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 24: 1385-1393, 2014.
9. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF and Ascierto PA: The immune score as a new possible approach for the classification of cancer. J Transl Med 10: 1, 2012.
10. Russell S, Angell T, Lechner M, Liebertz D, Correa A, Sinha U, Kokot N and Epstein A: Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol 5: 24, 2013.
11. Stewart TJ and Abrams SI: How tumours escape mass destruction. Oncogene 27: 5894-5903, 2008.
12. McDermott DF: Improving the therapeutic index of IL-2. Clin Adv Hematol Oncol 8: 862-864, 2010.
13. Shablak A, Sikand K, Shanks JH, Thistlethwaite F, Spencer-Shaw A and Hawkins RE: High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother 34: 107-112, 2011.
14. Lechner MG, Russell SM, Bass RS and Epstein AL: Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy 3: 1317-1340, 2011.
15. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P and Epstein AL: Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother 36: 477-489, 2013.
16. Liz J and Esteller M: lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta 1859: 169-176, 2016.
17. Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet 10: 155-159, 2009.
18. ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, et al: Long noncoding RNAs with enhancer-like function in human cells. Cell 143: 46-58, 2010.
19. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F and Fan Q: CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 38: 5366-5383, 2010.
20. Zhao X, Wang P, Liu J, Zheng J, Liu Y, Chen J and Xue Y: Gas5 exerts tumor-suppressive functions in human glioma cells by targeting MIR-222. Mol Ther 23: 1899-1911, 2015.
21. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E and Chang HY: Long noncoding RNA as modular scaffold of histone modification complexes. Science 329: 689-693, 2010.
22. Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. Mol Cell 43: 904-914, 2011.
23. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25: 666-681, 2014.
24. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A and Lawrence JB: An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell 33: 717-726, 2009.
25. Chen LL and Carmichael GG: Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: Functional role of a nuclear noncoding RNA. Mol Cell 35: 467-478, 2009.
26. Sasaki YT, Ideue T, Sano M, Mituyama T and Hirose T: MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc Natl Acad Sci USA 106: 2525-2530, 2009.
27. Sunwoo H, Dinger ME, Wilusz JE, Amaral PP, Mattick JS and Spector DL: MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome Res 19: 347-359, 2009.
28. Zeng C, Xu Y, Xu L, Yu X, Cheng J, Yang L, Chen S and Li Y: Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer 14: 693, 2014.
29. Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, et al: The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 5: 5383-5383, 2014.
30. Choudhry H, Albukhari A, Morotti M, Haider S, Moralli D, Smythies J, Schödel J, Green CM, Camps C, Buffa F, et al: Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene 34: 4546, 2015.
31. Guo S, Chen W, Luo Y, Ren F, Zhong T, Rong M, Dang Y, Feng Z and Chen G: Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. Int J Clin Exp Pathol 8: 5395-5402, 2015.
32. Kim YS, Hwan JD, Bae S, Bae DH and Shick WA: Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer 10: 576, 2010.
33. Li Z, Liu YH, Diao HY, Ma J and Yao YL: Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating MIR-449b-5p/c-Met axis. Tumour Biol 37: 673-683, 2016.
34. Frixa T, Donzelli S and Blandino G: Oncogenic MicroRNAs: key players in malignant transformation. Cancers (Basel) 7: 2466-2485, 2015.
35. Huntzinger E and Izaurralde E: Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet 12: 99-110, 2011.
36. Wang P, Liu YH, Yao YL, Li Z, Li ZQ, Ma J and Xue YX: Long non-coding RNA CASC2 suppresses malignancy in human gliomas by MIR-21. Cell Signal 27: 275-282, 2015.
37. Mardente S, Mari E, Massimi I, Fico F, Faggioni A, Pulcinelli F, Antonaci A and Zicari A: HMGB1-induced cross talk between PTEN and miRs 221/222 in thyroid cancer. Biomed Res Int 2015: 512027, 2015.
38. Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life 61: 1075-1082, 2009.
39. Wang F, Liu M, Li X and Tang H: MIR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett 587: 488-495, 2013.
40. Wen Z, Lei Z, Ma JA, Li XZ, Zheng XN and Deng XW: The inhibitory role of MIR-214 in cervical cancer cells through directly targeting mitochondrial transcription factor A (TFAM). Eur J Gynaecol Oncol 35: 676-682, 2014.
41. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al: Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 60: 598-609, 2014.
42. Long LM, He BF, Huang GQ, Guo YH, Liu YS and Huo JR: microRNA-214 functions as a tumor suppressor in human colon cancer via the suppression of ADP-ribosylation factor-like protein 2. Oncol Lett 9: 645-650, 2015.
43. Penna E, Orso F, Cimino D, Vercellino I, Grassi E, Quaglino E, Turco E and Taverna D: MIR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and MIR-148b downmodulation. Cancer Res 73: 4098-4111, 2013.
44. Yang TS, Yang XH, Wang XD, Wang YL, Zhou B and Song ZS: MIR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int 13: 68, 2013.
45. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: MicroRNA expression profiling in human ovarian cancer: MIR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433, 2008.
46. Gong W, Zheng J, Liu X, Ma J, Liu Y and Xue Y: Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e. Oncotarget: Aug 19, 2016 (Epub ahead of print).
47. Geisler S, Lojek L, Khalil AM, Baker KE and Coller J: Decapping of long noncoding RNAs regulates inducible genes. Mol Cell 45: 279-291, 2012.
48. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, et al: A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142: 409-419, 2010.
49. Barnhill LM, Williams RT, Cohen O, Kim Y, Batova A, Mielke JA, Messer K, Pu M, Bao L, Yu AL, et al: High expression of CAI2, a 9p21-embedded long noncoding RNA, contributes to advanced-stage neuroblastoma. Cancer Res 74: 3753-3763, 2014.
50. Nie FQ, Zhu Q, Xu TP, Zou YF, Xie M, Sun M, Xia R and Lu KH: Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. Tumour Biol 35: 7587-7594, 2014.
51. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F and Sun SH: Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49: 1083-1096, 2013.
52. Sun C, Li S, Zhang F, Xi Y, Wang L, Bi Y and Li D: Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of MIR-377-3p-E2F3 pathway. Oncotarget: Jun 16, 2016 (Epub ahead of print).
53. Naganuma T and Hirose T: Paraspeckle formation during the biogenesis of long non-coding RNAs. RNA Biol 10: 456-461, 2013.
54. Tani H, Torimura M and Akimitsu N: The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells. PLoS One 8: e55684, 2013.
55. Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W and Quan ZW: Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis 6: e1583-e1583, 2015.
56. Xiong X, Ren HZ, Li MH, Mei JH, Wen JF and Zheng CL: Down-regulated miRNA-214 induces a cell cycle G1 arrest in gastric cancer cells by up-regulating the PTEN protein. Pathol Oncol Res 17: 931-937, 2011.
57. Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY and Sun BC: Plexin-B1 is a target of MIR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol 43: 632-641, 2011.